Arvinas to Participate in Upcoming Investor Conferences
01 September 2023 - 9:00PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
three upcoming investor conferences:
- Wells Fargo 2023 Healthcare Conference on
Wednesday, September 6. Ron Peck, M.D., Chief Medical Officer, and
Sean Cassidy, Chief Financial Officer, will participate in a
fireside chat. A live audio webcast of the presentation will be
available here and on the Events and Presentations section of the
Company’s website.
- Morgan Stanley 21st Annual Global Healthcare
Conference on Tuesday, September 12. Ron Peck, M.D., Chief
Medical Officer, and Randy Teel, Ph.D., Senior Vice President,
Corporate and Business Development, will participate in a fireside
chat. A live audio webcast of the presentation will be available
here and on the Events and Presentations section of the Company’s
website.
- Cantor Global Healthcare Conference on
Thursday, September 28. Ron Peck, M.D., Chief Medical Officer, and
Sean Cassidy, Chief Financial Officer, will participate in a
fireside chat. A live audio webcast of the presentation will be
available here and on the Events and Presentations section of the
Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
bavdegalutamide and ARV-766 for the treatment of men with
metastatic castration-resistant prostate cancer; and vepdegestrant
(ARV-471) for the treatment of patients with locally advanced or
metastatic ER+/HER2- breast cancer. For more information, visit
www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203)
584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2024 to May 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2023 to May 2024